These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

564 related items for PubMed ID: 17826043

  • 1. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
    Mazzone T.
    Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
    [Abstract] [Full Text] [Related]

  • 2. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U, Pop-Busui R, Eagle KA.
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [Abstract] [Full Text] [Related]

  • 3. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control.
    Schneider CA.
    Curr Med Res Opin; 2006 Oct; 22 Suppl 2():S15-26. PubMed ID: 16914072
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L, Grassi D, Polidoro L, D'Aurelio A, Croce G, Properzi G, Tiberti S, Desideri G, Ferri C.
    J Nephrol; 2008 Oct; 21(6):826-35. PubMed ID: 19034866
    [Abstract] [Full Text] [Related]

  • 5. Type 2 diabetes mellitus: prevention of macrovascular complications.
    Meeuwisse-Pasterkamp SH, van der Klauw MM, Wolffenbuttel BH.
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994
    [Abstract] [Full Text] [Related]

  • 6. Prevention of coronary heart disease in type 2 diabetes.
    Mykkänen L.
    Int J Clin Pract Suppl; 2000 Oct; (113):40-5. PubMed ID: 11965831
    [Abstract] [Full Text] [Related]

  • 7. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA.
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [Abstract] [Full Text] [Related]

  • 8. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH.
    Am J Cardiol; 2007 Feb 19; 99(4A):133B-140B. PubMed ID: 17307065
    [Abstract] [Full Text] [Related]

  • 9. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A.
    Diabetes Metab Res Rev; 2009 Feb 19; 25(2):112-26. PubMed ID: 19219860
    [Abstract] [Full Text] [Related]

  • 10. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP.
    Diabetes Obes Metab; 2012 Nov 19; 14(11):973-82. PubMed ID: 22443197
    [Abstract] [Full Text] [Related]

  • 11. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A.
    Diabetes Metab Res Rev; 2008 Nov 19; 24(4):286-93. PubMed ID: 18273835
    [Abstract] [Full Text] [Related]

  • 12. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W.
    Herz; 2007 Feb 19; 32(1):51-7. PubMed ID: 17323035
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB.
    Pharmacotherapy; 2006 Feb 19; 26(2):168-81. PubMed ID: 16466323
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA, Lincoff AM.
    Am J Cardiovasc Drugs; 2010 Feb 19; 10(4):209-16. PubMed ID: 20653327
    [Abstract] [Full Text] [Related]

  • 20. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N, Ali MK, Narayan KM.
    Am J Cardiovasc Drugs; 2012 Feb 01; 12(1):7-22. PubMed ID: 22217193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.